S2215 |
DAPT
|
DAPT (GSI-IX、LY-374973) は新規の γ-セクレターゼ 阻害剤であり、HEK 293 細胞で 20 nM の IC50 で Aβ 産生を阻害します。 DAPT はヒト舌癌細胞のアポトーシス(apoptosis) を促進し、オートファジー (autophagy) を調節します。 |
-
Nat Biotechnol, 2024, 10.1038/s41587-024-02386-x
-
Nat Commun, 2024, 15(1):9529
-
J Clin Invest, 2024, 134(18)e179860
|
|
S1575 |
RO4929097
|
RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2. |
-
J Cell Physiol, 2024, 10.1002/jcp.31291
-
Cell Transplant, 2024, 33:9636897241288932
-
Res Sq, 2024, rs.3.rs-3843028
|
|
S2711 |
DBZ (Dibenzazepine)
|
DBZ (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively. |
-
Nat Commun, 2024, 15(1):9771
-
J Exp Clin Cancer Res, 2024, 43(1):295
-
Oncogene, 2024,
|
|
S2714 |
LY411575
|
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells. LY411575 induces apoptosis. |
-
Nat Commun, 2024, 15(1):8159
-
Cell Death Dis, 2024, 15(1):53
-
Cell Rep, 2024, 43(3):113837
|
|
S1262 |
Avagacestat (BMS-708163)
|
Avagacestat (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2. |
-
Nat Commun, 2022, 13(1):6345
-
Sci Rep, 2022, 12(1):7
-
Cell, 2021, 184(2):521-533.e14
|
|
S2660 |
MK-0752
|
MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2. |
-
Nat Cell Biol, 2024, 26(3):353-365
-
Cancers (Basel), 2023, 15(6)1883
-
J Cancer Res Clin Oncol, 2023, 149(16):14691-14699
|
|
S1594 |
Semagacestat (LY450139)
|
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3. |
-
Cancers (Basel), 2023, 15(6)1883
-
Sci Rep, 2022, 12(1):7
-
Calcif Tissue Int, 2022, 111(2):211-223
|
|
S8018 |
Nirogacestat (PF-03084014)
|
Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2. |
-
Int J Mol Sci, 2023, 24(17)13660
-
Int J Mol Sci, 2023, 24(17)13660
-
Cancers (Basel), 2023, 15(6)1883
|
|
S7673 |
L-685,458
|
L-685,458 is a specific and potent inhibitor of A beta PP gamma-secretase activity with Ki of 17 nM.
|
-
iScience, 2022, 25(10):105182
-
Biochem Biophys Res Commun, 2021, 570:137-142
-
Aging (Albany NY), 2020, 12(1):481-501
|
|
S7323 |
Itanapraced (CHF 5074)
|
Itanapraced (CHF 5074, CSP-1103) is a gamma-secretase modulator that reduces Aβ42 and Aβ40 secretion. The IC50s of CHF5074 for inhibition of COX-1 and COX-2 is above 100 μmol/L. |
|
|
E0465 |
Fosciclopirox
|
Fosciclopirox(CPX-POM) selectively delivers the active metabolite, Ciclopirox (CPX) that targets γ-secretase complex (Presenilin 1 and Nicastrin)2. It is used in the treatment of urothelial cancer and a number of solid and hematologic malignancies. |
|
|
S0058New |
Compound E
|
Compound E (γ-Secretase-IN-1) is a potent inhibitor of γ-secretase, which blocks γ-secretase-mediated cleavage of Notch with an IC50 of 0.32 nM. It also suppresses the production of β-amyloid(40) and β-amyloid(42) with IC50 values of 0.24 nM and 0.37 nM, respectively. It also inhibits Notch signalling, significantly disrupting gonadotropin-dependent follicle growth and halting progression to the preovulatory stage of development. |
|
|
E0079 |
Compound W
|
Compound W (3,5-Bis(4-nitrophenoxy)benzoic acid) is a 3,3'-diiodothyronine sulfate (3,3'-T2S) cross-reactive material in maternal serum, which can inhibit γ-secretase. |
|
|
S8603 |
NGP 555
|
NGP 555 is a small-molecule modulator of γ-secretase and has been successful in achieving good oral absorption, brain penetration, CNS activity, and specificity for a lipid-based membrane target preclinically. |
|
|
S2215 |
DAPT
|
DAPT (GSI-IX、LY-374973) は新規の γ-セクレターゼ 阻害剤であり、HEK 293 細胞で 20 nM の IC50 で Aβ 産生を阻害します。 DAPT はヒト舌癌細胞のアポトーシス(apoptosis) を促進し、オートファジー (autophagy) を調節します。 |
- Nat Biotechnol, 2024, 10.1038/s41587-024-02386-x
- Nat Commun, 2024, 15(1):9529
- J Clin Invest, 2024, 134(18)e179860
|
|
S1575 |
RO4929097
|
RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2. |
- J Cell Physiol, 2024, 10.1002/jcp.31291
- Cell Transplant, 2024, 33:9636897241288932
- Res Sq, 2024, rs.3.rs-3843028
|
|
S2711 |
DBZ (Dibenzazepine)
|
DBZ (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively. |
- Nat Commun, 2024, 15(1):9771
- J Exp Clin Cancer Res, 2024, 43(1):295
- Oncogene, 2024,
|
|
S2714 |
LY411575
|
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells. LY411575 induces apoptosis. |
- Nat Commun, 2024, 15(1):8159
- Cell Death Dis, 2024, 15(1):53
- Cell Rep, 2024, 43(3):113837
|
|
S1262 |
Avagacestat (BMS-708163)
|
Avagacestat (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2. |
- Nat Commun, 2022, 13(1):6345
- Sci Rep, 2022, 12(1):7
- Cell, 2021, 184(2):521-533.e14
|
|
S2660 |
MK-0752
|
MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2. |
- Nat Cell Biol, 2024, 26(3):353-365
- Cancers (Basel), 2023, 15(6)1883
- J Cancer Res Clin Oncol, 2023, 149(16):14691-14699
|
|
S1594 |
Semagacestat (LY450139)
|
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3. |
- Cancers (Basel), 2023, 15(6)1883
- Sci Rep, 2022, 12(1):7
- Calcif Tissue Int, 2022, 111(2):211-223
|
|
S8018 |
Nirogacestat (PF-03084014)
|
Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2. |
- Int J Mol Sci, 2023, 24(17)13660
- Int J Mol Sci, 2023, 24(17)13660
- Cancers (Basel), 2023, 15(6)1883
|
|
S7673 |
L-685,458
|
L-685,458 is a specific and potent inhibitor of A beta PP gamma-secretase activity with Ki of 17 nM.
|
- iScience, 2022, 25(10):105182
- Biochem Biophys Res Commun, 2021, 570:137-142
- Aging (Albany NY), 2020, 12(1):481-501
|
|
E0465 |
Fosciclopirox
|
Fosciclopirox(CPX-POM) selectively delivers the active metabolite, Ciclopirox (CPX) that targets γ-secretase complex (Presenilin 1 and Nicastrin)2. It is used in the treatment of urothelial cancer and a number of solid and hematologic malignancies. |
|
|
S0058New |
Compound E
|
Compound E (γ-Secretase-IN-1) is a potent inhibitor of γ-secretase, which blocks γ-secretase-mediated cleavage of Notch with an IC50 of 0.32 nM. It also suppresses the production of β-amyloid(40) and β-amyloid(42) with IC50 values of 0.24 nM and 0.37 nM, respectively. It also inhibits Notch signalling, significantly disrupting gonadotropin-dependent follicle growth and halting progression to the preovulatory stage of development. |
|
|
E0079 |
Compound W
|
Compound W (3,5-Bis(4-nitrophenoxy)benzoic acid) is a 3,3'-diiodothyronine sulfate (3,3'-T2S) cross-reactive material in maternal serum, which can inhibit γ-secretase. |
|
|